Laboratory Corporation of America
LHBusiness Overview
ticker: LH step: 01 generated: 2026-05-12 source: quick-research
Laboratory Corporation of America Holdings (LH) — Business Overview
Business Description
Labcorp (NYSE: LH) is one of the world's largest clinical laboratory networks, performing over 700 million tests annually for patients, physicians, hospitals, and pharmaceutical companies across approximately 100 countries. The company operates two segments: Diagnostics Laboratories (routine and specialty clinical testing) and Biopharma Laboratory Services (central lab services for clinical trials). Labcorp spun off its clinical research organization (CRO) operations as Fortrea (FTRE) in mid-2023, refocusing the core business on diagnostics and biopharma lab services.
Revenue Model
Revenue is generated primarily through fee-for-service diagnostic testing (reimbursed by Medicare, Medicaid, managed care, and direct patient payment), long-term contracts with health systems and hospitals for laboratory outreach services, and fixed-fee/variable contracts with pharmaceutical and biotech companies for central lab services in clinical trials. The Diagnostics segment (~80% of revenue) has high volume and recurring utilization driven by physician ordering patterns; Biopharma (~20%) is contract-driven and tied to clinical trial activity.
Products & Services
- Routine Diagnostics: Blood chemistry, CBC, urinalysis, microbiology — high-volume, lower-margin commodity tests
- Specialty Testing: Oncology genomics (Labcorp Plasma Complete ctDNA), women's health (prenatal, NIPT), neurology, autoimmune disease panels
- Genomics/NGS: Next-generation sequencing for cancer profiling, hereditary risk assessment, pharmacogenomics
- Biopharma Central Lab: Clinical trial specimen processing, biomarker testing, regulatory support for Phase I–IV trials
- LabCorp OnDemand: Direct-to-consumer testing (food allergies, micronutrients, thyroid, STI)
- Digital Pathology: AI-assisted pathology reads; partnerships with health systems
Customer Base & Go-to-Market
Physicians and hospital systems drive ~60% of diagnostic test volume; managed care and government payers (Medicare/Medicaid) are the primary payors. The company served over 75% of new FDA-approved drugs/therapies in clinical trial lab services in 2024. Hospital partnership strategy — 10 transactions in 2024, 13 in 2025 — involves taking over lab outreach operations for health systems, converting inbound volume and generating sticky long-term contracts.
Competitive Position
Labcorp and Quest Diagnostics (DGX) are the two dominant U.S. independent clinical laboratory companies, together controlling ~40% of the U.S. independent lab market. Labcorp's advantages include national network scale (2,000+ patient service centers), specialty testing breadth (130+ new tests launched in 2025), and deep biopharma central lab relationships. The hospital partnership model is creating structural market share gains — health system lab outreach programs generate 20–30% cost efficiencies that independent labs can offer vs. in-house hospital labs.
Key Facts
- Founded: 1978 (as National Health Laboratories)
- Headquarters: Burlington, North Carolina
- Employees: ~70,000
- Exchange: NYSE
- Sector / Industry: Health Care / Health Care Services
- Market Cap: ~$19B
Financial Snapshot
ticker: LH step: 04 generated: 2026-05-12 source: quick-research
Laboratory Corporation of America Holdings (LH) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | $14.95B | $12.16B | $13.01B | +7.0% |
| Gross Margin | ~30% | ~28% | ~29% | |
| Operating Margin | ~10% | ~7% | ~7.4% | |
| Net Income | ~$1.5B | ~$750M | ~$830M | |
| EPS (diluted, non-GAAP) | ~$16.50 | ~$14.00 | ~$15.80 | +13% |
FY2022 revenue was elevated by residual COVID-19 PCR testing volumes. FY2023 decline reflects the COVID testing winddown and the Fortrea CRO spin-off (mid-2023), which removed ~$2.5B in CRO revenue from the consolidated entity. FY2024 and forward comparisons are on the cleaner, post-Fortrea diagnostics-focused basis.
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$1.6B |
| Free Cash Flow | ~$1.1B |
| Capital Expenditures | ~$500M |
| Cash & Equivalents | ~$800M |
| Total Debt | ~$5.5B |
Key Ratios (approximate)
- P/E: ~15x (non-GAAP) | EV/EBITDA: ~10x | FCF Yield: ~5.5%
- Revenue Growth (FY2024): +7.0% | FCF Margin: ~8.5%
- Dividend Yield: ~1.2%
Growth Profile
Post-Fortrea spin-off, Labcorp is a cleaner diagnostics and biopharma services story. The FY2023 base was depressed by the COVID testing cliff and Fortrea removal; FY2024's +7% growth reflects organic Diagnostics volume recovery, hospital partnership acquisitions, and Biopharma Central Lab growth. FY2025 continued strong at ~$14.0B revenue (+7.7% YoY), driven by specialty testing expansion (130+ new tests launched), hospital partnership wins (13 transactions), and sustained biopharma demand. Specialty testing (oncology, women's health, NGS genomics) carries materially higher margins than routine testing and is the primary earnings growth driver.
Forward Estimates
- FY2025 Revenue: ~$14.0B (actual, +7.7% YoY)
- FY2026 Revenue Guidance: +4.7%–6.0% growth (~$14.7B–$14.8B)
- FY2026 Adjusted EPS Guidance: $17.55–$18.25 (midpoint $17.90, +8.9% YoY)
- FY2026 FCF Guidance: $1.24B–$1.36B
- PAMA reimbursement cuts frozen for 2026 (resume in 2027 at max 15%/year through 2029)
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $LH.